Peking Union Medical College Hospital: Lymphoma trials

The registry lists 22 Lymphoma studies with Peking Union Medical College Hospital as lead sponsor. 11 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 8Phase 2 14Phase 3 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell LymphomaRecruitingNCT06824883Phase 2
• Golidocitinib Plus CHOP in Newly Diagnosed PTCLRecruitingNCT06739265Phase 1/2
• Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.RecruitingNCT06454968Phase 2
• Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center StudyRecruitingNCT06083701Phase 1/2
• Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center StudyRecruitingNCT06037239Phase 1/2
• Construction of Diagnosis and Treatment System for Primary Vitreoretinal LymphomaRecruitingNCT05950490
• Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCLRecruitingNCT05441761Phase 1/2
• Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSLRecruitingNCT05390749Phase 2
• Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell LymphomaRecruitingNCT05075460Phase 3
• Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCLRecruitingNCT05054426Phase 3
• Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal LymphomaRecruitingNCT03746223Phase 2
• Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell LymphomaStatus unknownNCT05179213Phase 2
• Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRLStatus unknownNCT04899453Phase 2
• Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System LymphomaStatus unknownNCT04899427Phase 2
• A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's LymphomaCompletedNCT04655677Phase 1
• Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II StudyStatus unknownNCT04296786Phase 2
• R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II StutyStatus unknownNCT04120350Phase 1/2
• A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL SubjectsCompletedNCT03483688Phase 1
• Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and LymphomaStatus unknownNCT03436342Early Phase 1
• Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL PatientsStatus unknownNCT03079947
• The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of LymphomasStatus unknownNCT03000738
• Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell LymphomaStatus unknownNCT02987244Phase 1/2